Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that the new indication – adult patients with chronic-phase chronic myeloid leukemia (CML-CP) resistant and/or intolerant of first-and second-generation tyrosine kinase inhibitors (TKIs) – of its novel drug, olverembatinib (HQP1351), has been included into the China 2024 National Reimbursement Drug List (NRDL), effective January 1, 2025. This indication was added to the NRDL...